ArticlePediatric radiology2025
T2-weighted MRI radiomics for the prediction of pediatric and young adult rhabdomyosarcoma alveolar subtype and distant metastasis: a pilot study.
Article in Pediatric radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionRhabdomyosarcomas are the most common soft tissue sarcoma in children. While treatment outcomes have improved, risk-based therapy classification relies on staging and tumor subtypes for therapeutic planning.
objectiveThis study investigated the utility of T2-weighted MR radiomics features and machine learning models in identifying the presence of distant metastasis and alveolar histological subtypes at baseline imaging in children diagnosed with rhabdomyosarcoma. MATERIALS AND
methodsThis retrospective cross-sectional study utilized MRIs from 86 patients, 49 (median age (IQR) 59 months (37-161), alveolar subtype=15, distant metastasis=9) of whom had been imaged at outside imaging centers (training set); and 37 (median age 52 months (24-164), alveolar subtype=14, distant metastasis=8) of whom were imaged at our institution (holdout validation set). Radiomic features were extracted from T2-weighted images. We selected features that demonstrated intra-scan repeatability and used maximum relevance and minimum redundancy supervised feature selection to identify the 50 most important features. Lasso logistic regression and support vector machine (SVM) classifiers were trained to predict binary outcomes. The median of all predictions for a given patient was used as patient-level predictions. DeLong's test compared the area under the receiver operating characteristic curves (AUC). Cut-offs obtained by maximizing the Youden index were evaluated on an external validation set, and accuracy metrics were reported.
resultsOn the validation set, the Lasso and SVM classifiers obtained patient level AUCs of 0.76 (95% CI 0.59-0.94) and 0.73 (0.54-0.92), respectively, in predicting alveolar subtype, with the Lasso regressor obtaining 71.4% (41.9-91.6) sensitivity and 60.9% (38.5-80.3) specificity. When predicting the presence of distant metastasis, the Lasso and SVM classifier had AUCs of 0.81 (0.67-0.95) and 0.77 (0.58-0.97), respectively. There were no differences between model performance (P>0.05). A total of 12 and 18 features had nonzero coefficients in the Lasso regressors for predicting alveolar subtype and tumor metastasis, respectively.
conclusionMRI radiomics from baseline T2-weighted MRI demonstrated potential in predicting alveolar subtype and distant metastatic disease at presentation. Larger studies are needed to explore multinomial multiclass models for better prognostication of pediatric rhabdomyosarcomas.
Indexed as
Identifiers
40100409What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.